journal
MENU ▼
Read by QxMD icon Read
search

Diabetes & Metabolism

journal
https://www.readbyqxmd.com/read/28648835/effect-of-glp-1-receptor-agonist-on-gastrointestinal-tract-motility-and-residue-rates-as-evaluated-by-capsule-endoscopy
#1
Y Nakatani, M Maeda, M Matsumura, R Shimizu, N Banba, Y Aso, T Yasu, H Harasawa
AIM: This study evaluated the effects of a glucagon-like peptide-1 receptor agonist on gastrointestinal (GI) tract motility and residue rates by examining GI transit time and lumen using capsule endoscopy. MATERIAL AND METHODS: GI motility and lumen were assessed by capsule endoscopy before and after liraglutide administration in 14 patients with type 2 diabetes mellitus (T2DM). RESULTS: Gastric transit time in the group with diabetic neuropathy (DN) was 1:12:36±1:04:30h before liraglutide administration and 0:48:40±0:32:52h after administration (nonsignificant difference, P=0...
June 22, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28648834/combination-avelumab-and-utomilumab-immunotherapy-can-induce-diabetic-ketoacidosis
#2
LETTER
P W Atkins, D M Thompson
No abstract text is available yet for this article.
June 22, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28622950/glycaemic-control-and-hypoglycaemia-with-insulin-glargine-300u-ml-versus-insulin-glargine-100u-ml-in-insulin-na%C3%A3-ve-people-with-type-2%C3%A2-diabetes-12-month-results-from-the-edition-3-trial
#3
G B Bolli, M C Riddle, R M Bergenstal, M Wardecki, H Goyeau, P D Home
AIM: To explore if efficacy and safety findings for insulin glargine 300U/mL (Gla-300) versus insulin glargine 100U/mL (Gla-100), observed over 6 months in insulin-naïve people with type 2 diabetes, are maintained after 12 months. METHODS: EDITION 3 was a phase 3a, randomized, multicentre, open-label, parallel-group, treat-to-target study of once-daily Gla-300 versus Gla-100 (target fasting self-monitored plasma glucose, 4.4-5.6mmol/L [80-100mg/dL]). Participants completing the initial 6-month treatment phase continued their previously allocated basal insulin...
June 13, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28602488/higher-parathyroid-hormone-levels-are-associated-with-increased-below-the-knee-arterial-calcification-in-type%C3%A2-2-diabetes
#4
LETTER
A Mary, A Hartemann, M Brazier, C E Aubert, S Kemel, J E Salem, P Cluzel, S Liabeuf, Z Massy, R Mentaverri, O Bourron, S Kamel
No abstract text is available yet for this article.
June 8, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28599764/different-insulin-concentrations-in-resuspended-vs-unsuspended-nph-insulin-practical-aspects-of-subcutaneous-injection-in-patients-with-diabetes
#5
P Lucidi, F Porcellati, A Marinelli Andreoli, P Candeloro, P Cioli, G B Bolli, C G Fanelli
AIMS: This study measured the insulin concentration (Ins[C]) of NPH insulin in vials and cartridges from different companies after either resuspension (R+) or not (R-; in the clear/cloudy phases of unsuspended NPH). METHODS: Measurements included Ins[C] in NPH(R+) and in the clear/cloudy phases of NPH(R-), and the time needed to resuspend NPH and time for NPH(R+) to separate again into clear/cloudy parts. RESULTS: In vials of NPH(R+) (assumed to be 100%), Ins[C] in the clear phase of NPH(R-) was<1%, but 230±41% and 234±54% in the cloudy phases of Novo Nordisk and Eli Lilly NPH, respectively...
June 6, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28583347/plasma-trans-palmitoleic-acid-is-associated-with-cardio-metabolic-risk-factors-in-youth-with-type-1-diabetes
#6
LETTER
N S The, I B King, S C Couch, J L Crandell, D Dabelea, A D Liese, E J Mayer-Davis
No abstract text is available yet for this article.
June 2, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28579289/effects-of-anti-somatostatin-agents-on-glucose-metabolism
#7
REVIEW
B Vergès
The anti-somatostatin agents used to treat acromegaly, Cushing's disease and neuroendocrine tumours also have hyperglycaemic effects. This is particularly true for pasireotide. Hyperglycaemic events are seen in 57-73% of patients with Cushing's treated with pasireotide, with a need to initiate antidiabetic treatment in about 50% of these patients. In acromegaly, treatment with pasireotide induces hyperglycaemia in 29-61% of patients. Pasireotide-induced hyperglycemia occurs early, within the first 3 months of treatment, due to a decrease in insulin secretion secondary to a fall in secretion of GLP-1 and GIP, and potentially also due to a direct inhibitory effect of pasireotide on beta cells...
June 1, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28579156/the-type%C3%A2-2-diabetes-susceptibility-tcf7l2-gene-variants-affect-postprandial-glucose-and-fat-utilization-in-non-diabetic-subjects
#8
LETTER
E Adamska, A Kretowski, J Goscik, A Citko, W Bauer, M Waszczeniuk, K Maliszewska, M Paczkowska-Abdulsalam, M Niemira, L Szczerbinski, M Ciborowski, M Gorska
No abstract text is available yet for this article.
May 31, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28571922/a-decrease-in-glutamic-acid-decarboxylase-autoantibody-levels-with-sitagliptin-use-in-patients-with-latent-autoimmune-diabetes-in-adults
#9
LETTER
H Yanai
No abstract text is available yet for this article.
May 29, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28552491/-treatment-resistant-type-2-diabetes-which-definition-for-clinical-practice
#10
EDITORIAL
A J Scheen
No abstract text is available yet for this article.
May 25, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28549774/comparison-of-simple-indices-for-measuring-insulin-resistance-that-integrates-adipokines-in-non-diabetic-obese-postmenopausal-women-before-and-after-weight-loss-a-monet-study
#11
LETTER
C Vatier, S Fellahi, A D Karelis, M Brochu, E Doucet, D Prud'homme, R Rabasa-Lhoret, J-P Bastard
No abstract text is available yet for this article.
May 23, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28527866/informal-caregiving-as-a-risk-factor-for-type-2-diabetes-in-individuals-with-favourable-and-unfavourable-psychosocial-work-environments-a-longitudinal-multi-cohort-study
#12
J Mortensen, A J Clark, T Lange, G S Andersen, M Goldberg, C H Ramlau-Hansen, J Head, M Kivimäki, I E H Madsen, C Leineweber, R Lund, R Rugulies, M Zins, H Westerlund, N H Rod
AIM: To examine whether informal caregiving is associated with increased risk of type 2 diabetes (T2D), and whether job strain and social support at work modify the association. METHODS: Individual participant's data were pooled from three cohort studies-the French GAZEL study, the Swedish Longitudinal Occupational Survey of Health (SLOSH) and the British Whitehall II study-a total of 21,243 study subjects. Informal caregiving was defined as unpaid care for a closely related person...
May 17, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28526322/low-serum-creatinine-is-a-type-2-diabetes-risk-factor-in-men-and-women-the-yuport-health-checkup-center-cohort-study
#13
S Kashima, K Inoue, M Matsumoto, K Akimoto
AIM: Type 2 diabetes (T2D) is a risk factor for muscle loss and subsequent frailty. The reverse association, however, may also happen. This study examined whether serum creatinine level, an indicator of muscle mass, predicted diabetes development. In addition, a role for body mass index (BMI) as an effect modifier of creatinine levels was evaluated. METHODS: This cohort study included 9667 subjects without diabetes or hypertension and with normal creatinine levels at baseline...
May 16, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28522196/impact-of-glucose-lowering-therapies-on-risk-of-stroke-in-type-2-diabetes
#14
REVIEW
F Bonnet, A J Scheen
Patients with type 2 diabetes (T2D) have an increased risk of stroke compared with people without diabetes. However, the effects of glucose-lowering drugs on risk of ischaemic stroke in T2D have been less extensively investigated than in coronary heart disease. Some evidence, including the UKPDS, has suggested a reduced risk of stroke with metformin, although the number of studies is limited. Inhibition of the KATP channels increases ischaemic brain lesions in animals. This is in agreement with a recent meta-analysis showing an increased risk of stroke with sulphonylureas vs...
May 15, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28499696/fenofibrate-decreases-plasma-ceramide-in-type-2-diabetes-patients-a-novel-marker-of-cvd
#15
M Croyal, Z Kaabia, L León, S Ramin-Mangata, T Baty, F Fall, S Billon-Crossouard, A Aguesse, T Hollstein, D R Sullivan, E Nobecourt, G Lambert, M Krempf
AIM: The benefit of the lipid-lowering drug fenofibrate on cardiovascular outcomes is controversial. Our aim was to find new circulating markers to identify those patients most likely to benefit from fenofibrate prescription. METHODS: Analyses were conducted of plasma samples collected from 102 patients with type 2 diabetes, enrolled in the FIELD trial, before and after fenofibrate treatment (200mg/day). Non-targeted and targeted lipid analyses and apolipoprotein measurements were made using mass spectrometry methods...
May 9, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28499695/dapagliflozin-modulates-glucagon-secretion-in-an-sglt2-independent-manner-in-murine-alpha-cells
#16
A Solini, G Sebastiani, L Nigi, E Santini, C Rossi, F Dotta
AIM: SGLT2 inhibitors reduce renal glucose uptake through an insulin-independent mechanism. They also increase glucagon concentration, although the extent to which this is due to a direct effect on pancreatic alpha cells remains unclear. METHODS: In the present work, αTC1 cells treated with the SGLT2 inhibitor dapagliflozin (Dapa) were analyzed for glucose transporters, molecular mediators of hormone secretion, glucagon and GLP-1 release, and the effects of somatostatin...
May 9, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28495365/the-yin-and-yang-of-apolipoprotein-ciii
#17
LETTER
K Åvall, P-O Berggren, L Juntti-Berggren
No abstract text is available yet for this article.
May 8, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28483292/acute-pancreatitis-with-dipeptidyl-peptidase-4-dpp4-inhibitor-or-fulminant-type-1-diabetes
#18
LETTER
C Amouyal, P Levy, F Andreelli, A Hartemann
No abstract text is available yet for this article.
May 5, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28483291/psychosocial-determinants-of-non-adherence-to-antidiabetic-drug-treatment-a-prospective-cohort-study
#19
LETTER
L Guénette, A Zongo, L Guillaumie, S Lauzier, L Blais, J-P Grégoire, J Moisan
No abstract text is available yet for this article.
May 5, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28476578/canagliflozin-as-a-replacement-therapy-for-patients-with-type-2-diabetes-not-responding-to-glp-1-receptor-agonists
#20
LETTER
M D Garcia de Lucas, J Olalla Sierra
No abstract text is available yet for this article.
May 2, 2017: Diabetes & Metabolism
journal
journal
32535
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"